ProMIS Neurosciences Inc (PMN.CA) Stock Price, Forecast & Analysis
Canada • Toronto Stock Exchange • TSX:PMN • CA74346M4065
PMN.CA Key Statistics, Chart & Performance
The current stock price of PMN.CA is 6 CAD. In the past month the price increased by 10.91%. In the past year, price decreased by -22.08%.
PMN.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PMN.CA. When comparing the yearly performance of all stocks, PMN.CA is a bad performer in the overall market: 79% of all stocks are doing better.
PMN.CA Financial Highlights
Over the last trailing twelve months PMN.CA reported a non-GAAP Earnings per Share(EPS) of -3.5. The EPS decreased by -203.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PMN.CA Forecast & Estimates
5 analysts have analysed PMN.CA and the average price target is 26.52 CAD. This implies a price increase of 342% is expected in the next year compared to the current price of 6.
PMN.CA Ownership
PMN.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 580.449M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 375.908M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 139.775M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 68.396M | ||
| COV | COVALON TECHNOLOGIES LTD | 12.86 | 43.916M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.57 | 31.273M | ||
| RVX | RESVERLOGIX CORP | N/A | 30.171M | ||
| HEM | HEMOSTEMIX INC | N/A | 16.964M | ||
| MPH | MEDICURE INC | N/A | 12.006M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 10.716M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About PMN.CA
Company Profile
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. The company is headquartered in Toronto, Ontario and currently employs 6 full-time employees. The company went IPO on 2005-09-30. The firm is engaged in the development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The firm operates through a single segment: Canada. The firm's discovery engine comprises two complementary algorithms, ProMIS, and Collective Coordinates. The Company’s complementary algorithms predict and identify novel targets known as Disease Specific Epitopes (DSEs). Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The firm also plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB), and schizophrenia. The firm's subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
Company Info
ProMIS Neurosciences Inc
Suite 200, 1920 Yonge Street
TORONTO ONTARIO M4S 3E2 CA
CEO: Elliot Goldstein
Employees: 6
Phone: 14168476898.0
ProMIS Neurosciences Inc / PMN.CA FAQ
What does PMN do?
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. The company is headquartered in Toronto, Ontario and currently employs 6 full-time employees. The company went IPO on 2005-09-30. The firm is engaged in the development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The firm operates through a single segment: Canada. The firm's discovery engine comprises two complementary algorithms, ProMIS, and Collective Coordinates. The Company’s complementary algorithms predict and identify novel targets known as Disease Specific Epitopes (DSEs). Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The firm also plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB), and schizophrenia. The firm's subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
Can you provide the latest stock price for ProMIS Neurosciences Inc?
The current stock price of PMN.CA is 6 CAD. The price decreased by -3.85% in the last trading session.
Does PMN stock pay dividends?
PMN.CA does not pay a dividend.
How is the ChartMill rating for ProMIS Neurosciences Inc?
PMN.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is ProMIS Neurosciences Inc (PMN.CA) stock traded?
PMN.CA stock is listed on the Toronto Stock Exchange exchange.